SCILEX HOLDING CO
SCLX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SCLX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SCLX
Scilex Holding Co. is a commercial-stage biopharmaceutical company focused on developing and commercializing non-opioid pain management products, including ZTlido, GLOPERBA, and ELYXYB, but faces significant financial challenges with negative working capital and a going concern uncertainty.
Key risk: Going concern risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$38.2M
Cash Runway
3.8 moLead Asset
sp-102 (Phase 3)
Next Catalyst
Patent_Expiry · May 10, 2031Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 catalysts for SCILEX HOLDING CO.
Scilex Holding Co. is a commercial-stage biopharmaceutical company focused on developing and commercializing non-opioid pain management products, including ZTlido, GLOPERBA, and ELYXYB, but faces significant financial challenges with negative working capital and a going concern uncertainty.
- Scilex markets three non-opioid pain products: ZTlido (lidocaine topical system), GLOPERBA (colchicine), and ELYXYB (celecoxib oral solution) [sec_mda · as of 2026-04-10].
- As of June 30, 2026, the company had cash and equivalents of $0.6 million, negative working capital of $476.0 million, and an accumulated deficit of $1.1 billion [sec_mda · as of 2026-08-14].
- For the six months ended June 30, 2026, Scilex reported operating losses of $61.6 million and cash used in operating activities of $7.8 million [sec_mda · as of 2026-08-14].
- Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year after the issuance of its financial statements [sec_mda · as of 2026-04-10].
- The company plans to obtain additional resources through equity offerings, debt financings, or collaborations to fund operations and service debt obligations [sec_mda · as of 2026-08-14].
What works
- Scilex has three approved commercial products (ZTlido, GLOPERBA, ELYXYB) targeting the large non-opioid pain market, providing a diversified revenue base [sec_mda · as of 2026-04-10].
- The company is investing in sales and marketing and digital efforts to broaden awareness of its products, which could drive revenue growth [sec_mda · as of 2026-04-10].
- Scilex has patent protection extending to 2031-2037 for its key products, offering potential long-term market exclusivity [upcoming catalysts].
What to weigh
- As of June 30, 2026, Scilex had only $0.6 million in cash and a negative working capital of $476 million, indicating severe liquidity constraints [sec_mda · as of 2026-08-14].
- The company has an accumulated deficit of $1.1 billion and continues to incur operating losses, with $61.6 million in losses for the first half of 2026 [sec_mda · as of 2026-08-14].
- Management has expressed substantial doubt about the company's ability to continue as a going concern, highlighting the risk of insufficient capital to fund operations [sec_mda · as of 2026-04-10].
- Scilex faces significant debt obligations and may need to raise additional capital on unfavorable terms, potentially diluting existing shareholders [sec_mda · as of 2026-04-10].
From the filings
Quoted directly from source documents.
Severe liquidity position with negative working capital
“As of June 30, 2026, the Company's negative working capital was $ 476.0 million , including cash and cash equivalents of approximately $ 0.6 million .”
SEC MD&A · August 14, 2026
Going concern uncertainty
“Our management has concluded that there is substantial doubt about our ability to continue as a going concern for one year after the date that the consolidated financial statements are issued.”
SEC MD&A · April 10, 2026
High accumulated deficit
“The Company had an accumulated deficit of $ 1.1 billion as of June 30, 2026.”
SEC MD&A · August 14, 2026
Operating losses continue
“During the six months ended June 30, 2026, the Company had operating losses of $ 61.6 million and cash flows used in operating activities of $ 7.8 million .”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2031-05-10 · Patent_Expiry · ZTLIDO — Patent/exclusivity expiry for ZTlido; potential generic competition may impact revenue.
- 2036-05-27 · Patent_Expiry · ELYXYB — Patent/exclusivity expiry for ELYXYB; long-term market exclusivity ends.
- 2037-12-20 · Patent_Expiry · GLOPERBA — Patent/exclusivity expiry for GLOPERBA; potential generic entry after this date.
Risks & what to watch (4)›
Key risks
- Going concern risk — Management has concluded substantial doubt about ability to continue as a going concern within one year [sec_mda · as of 2026-04-10].
- Liquidity and capital needs — Cash of only $0.6M and negative working capital of $476M as of June 30, 2026; needs additional financing [sec_mda · as of 2026-08-14].
- Debt service obligations — Total debt of $80.8M as of June 30, 2026; may need to raise capital on unfavorable terms to service debt [sec_mda · as of 2026-04-10].
- Nasdaq listing compliance — Risk of not maintaining Nasdaq listing, which could impact stock liquidity and trading [sec_mda · as of 2026-08-14].
What to watch
- Ability to raise additional capital through equity or debt offerings to fund operations and service debt [sec_mda · as of 2026-08-14].
- Revenue growth trajectory of ZTlido, GLOPERBA, and ELYXYB, and whether sales materialize at anticipated rates [sec_mda · as of 2026-04-10].
- Maintenance of Nasdaq listing and any potential delisting risk [sec_mda · as of 2026-08-14].
- Progress in clinical development and regulatory approvals for expanded indications [sec_mda · as of 2026-04-10].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run SCILEX HOLDING CO through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SCILEX HOLDING CO facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
3.8 months
OCF -$9M · Net income -$115M
Lead: Phase 3
3 candidates
3 upcoming, next in ~1714d
2 buys · 1 sell (180d)
Runway
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
70
Total value held
$7.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 528,100 | $3.5M |
| armistice capital, llc | 297,706 | $2.0M |
| blackrock, inc. | 102,796 | $685K |
| vanguard fiduciary trust co | 39,658 | $264K |
| renaissance technologies llc | 36,864 | $246K |
| state street corp | 35,376 | $236K |
| xtx topco ltd | 22,606 | $151K |
| northern trust corp | 15,033 | $100K |
| morgan stanley | 11,973 | $80K |
| citigroup inc | 8,954 | $60K |
Showing top 10 of 70 institutional holders of SCILEX HOLDING CO. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 3.4%
- Days to cover
- 5.8
- Shares short
- 187,953
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SCLX short interestGovernance
Frequently asked questions
What is the AI investment thesis for SCILEX HOLDING CO?
Scilex Holding Co. is a commercial-stage biopharmaceutical company focused on developing and commercializing non-opioid pain management products, including ZTlido, GLOPERBA, and ELYXYB, but faces significant financial challenges with negative working capital and a going concern uncertainty.
What is SCILEX HOLDING CO's lead drug candidate?
SCILEX HOLDING CO's most advanced tracked candidate is sp-102 (Phase 3) for lumbosacral radicular pain, or sciatica.
What is SCILEX HOLDING CO's next catalyst?
SCILEX HOLDING CO's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ZTLIDO" — expected May 10, 2031.
Who is the CEO of SCILEX HOLDING CO?
Dr. Henry H. Ji Ph.D. is the chief executive officer of SCILEX HOLDING CO (SCLX).
Where is SCILEX HOLDING CO headquartered?
SCILEX HOLDING CO (SCLX) is headquartered in Palo Alto, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.